SCHEMBL2432926

SCHEMBL2432926

N#Cc1c(F)cccc1[Zn]

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.43
▸ KDM4E B2RXH2 5/20 0.43
▸ HPGD P15428 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ MAPT P10636 2/20 0.39
▸ KMT2A Q03164 2/20 0.37
▸ TRPV4 Q9HBA0 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ CACNA1B Q00975 1/20 0.37
▸ APBA1 Q02410 1/20 0.37
▸ ADORA1 P30542 4/20 0.37
▸ ADORA2A P29274 3/20 0.37
▸ CUL4A Q13619 1/20 0.35
▸ TAS1R3 Q7RTX0 1/20 0.35
▸ TAS1R1 Q7RTX1 1/20 0.35
▸ TAS1R2 Q8TE23 1/20 0.35
▸ EEF2K O00418 1/20 0.34
▸ ADORA2B P29275 3/20 0.34
▸ POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Iodide SCHEMBL2428913 0.98 ALDH1A1 (0.42) ALDH1A1KDM4EHPGDHSD17B10MAPT
SCHEMBL186269 0.83 ALDH1A1 (0.50) ALDH1A1KDM4EHPGDHSD17B10MAPT
Cyanide SCHEMBL28871133 0.78 ALDH1A1 (0.47) ALDH1A1KDM4EHPGDHSD17B10MAPT
SCHEMBL165576 0.77 ALDH1A1 (0.43) ALDH1A1KDM4EHPGDHSD17B10MAPT
SCHEMBL30628861 0.77 ALDH1A1 (0.43) ALDH1A1KDM4EHPGDHSD17B10MAPT
SCHEMBL19062287 0.76 ALDH1A1 (0.46) ALDH1A1KDM4EHPGDHSD17B10MAPT
SCHEMBL2569036 0.76 ADORA1 (0.46) ALDH1A1KDM4EHPGDHSD17B10KMT2A
SCHEMBL186554 0.74 KDM4E (0.44) ALDH1A1KDM4EHPGDHSD17B10MAPT
SCHEMBL186023 0.73 KDM4E (0.47) ALDH1A1KDM4EHPGDHSD17B10KMT2A
SCHEMBL286715 0.73 CYP1A2 (0.50) ALDH1A1KDM4EHPGDHSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110319426-A1 Substituted Isoindoles ASTRAZENECA AB (SE) 2011-12-29 — — US disclosed
US-8030500-B2 Substituted isoindoles for the treatment and/or prevention of Aβ- related pathologies ASTRAZENECA AB (SE) 2011-10-04 — — US disclosed
EP-2367814-A1 NEW COMPOUNDS 578 AstraZeneca AB (SE) 2011-09-28 — — EP disclosed
US-20100125082-A1 NEW COMPOUNDS 578 ASTRAZENECA AB (SE) 2010-05-20 — — US disclosed
WO-2010056196-A1 NEW COMPOUNDS 578 ASTRAZENECA AB (SE) 2010-05-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100125082-A1 NEW COMPOUNDS 578 PSEN1, PSEN2, BACE1 ALDH1A1 4118/4885KDM4E 4149/4885HPGD 2286/4885
US-20110319426-A1 Substituted Isoindoles PSEN2, PSEN1, SNCA ALDH1A1 3507/4885KDM4E 4394/4885HPGD 1836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback